Capillary OGTT and home testing in children at risk of diabetes
What this study tests
Recruiting UK study comparing finger-prick glucose with venous OGTT and testing whether a capillary OGTT can be performed acceptably at home. Its T1D cohorts include young people with multiple islet autoantibodies, but the wider study also includes children being assessed for type 2 diabetes.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-04-13.
Most recent recorded citation date: 2026-04-13. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- People under 18 undergoing an OGTT; the at-risk T1D home-testing cohorts require two or more islet autoantibodies. A separate cohort includes young people with prediabetes. See the registry for full criteria. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted. The study is recruiting an estimated 135 participants at four UK sites, with primary completion estimated in February 2027 and full completion in August 2027. It tests measurement and feasibility, not whether home OGTT changes progression or clinical outcomes.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United Kingdom. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Agreement between capillary and venous glucose during OGTT
- Feasibility of using the capillary OGTT device at home
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT06815081: Capillary OGTT Study · Trial registry · 2026-04-13 — RECRUITING observational study; estimated n=135; four UK sites; actual start 29 February 2024, primary completion February 2027, and completion August 2027. The protocol includes both T1D-risk and T2D/prediabetes cohorts.